A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer

This study is currently recruiting participants.

Verified by Alberta Cancer Board, July 2006

Sponsored by:	Alberta Cancer Board
Information provided by:	Alberta Cancer Board
ClinicalTrials.gov Identifier:	NCT00122291

Purpose

The purpose of this trial is to study the efficacy of preoperative radiation therapy and capecitabine in locally advanced rectal cancer.

Condition	Intervention	Phase
Rectal Cancer Neoplasm Metastasis	Drug: Capecitabine Procedure: Pelvic radiation	Phase II

MedlinePlus related topics: Cancer

Drug Information available for: Capecitabine

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	A Phase 2 Study of Preoperative Radiation Therapy and Capecitabine (an Oral Fluoropyrimidine Carbamate) in Locally Advanced Rectal Cancer

Further study details as provided by Alberta Cancer Board:

Primary Outcome Measures:

Estimated Enrollment:	66
Study Start Date:	January 2002

Detailed Description:

The purpose of this trial is to study the efficacy of preoperative radiation therapy and capecitabine in locally advanced rectal cancer.

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00122291

Contacts

Contact: Alexander Chan, MD	403-521-3013	alexc@cancerboard.ab.ca
Contact: Alfred Wong, MD

Locations

Sponsors and Collaborators

Alberta Cancer Board

Investigators

Principal Investigator:

Alexander Chan, MD

Alberta Cancerboard

More Information

Study ID Numbers:	Capcetabine Phase 2, 16080
Study First Received:	July 20, 2005
Last Updated:	July 12, 2006
ClinicalTrials.gov Identifier:	NCT00122291
Health Authority:	Canada: Health Canada

Keywords provided by Alberta Cancer Board:

preoperative
chemotherapy
radiation therapy

rectal cancer
transmural rectal wall invasion
nodal metastasis

Study placed in the following topic categories:

Capecitabine
Digestive System Neoplasms
Rectal Neoplasms
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Intestinal Neoplasms

Rectal neoplasm
Digestive System Diseases
Neoplasm Metastasis
Gastrointestinal Neoplasms
Rectal cancer
Colorectal Neoplasms

Additional relevant MeSH terms:

Antimetabolites
Neoplastic Processes
Neoplasms
Antimetabolites, Antineoplastic
Pathologic Processes

Neoplasms by Site
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009